Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.31 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.31 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441727 | 1.00 | NTRK1 (0.38) | NTRK1FYNFGFR4PIM1PIM2 | |
| SCHEMBL1440946 | 0.79 | CDK2 (0.39) | NTRK1FYNPIM1NTRK3 | |
| SCHEMBL1442102 | 0.79 | PIM1 (0.36) | NTRK1FYNPIM1PIM2NTRK3 | |
| SCHEMBL15261764 | 0.79 | PIM1 (0.44) | FYNFGFR4PIM1PIM2 | |
| SCHEMBL16083391 | 0.72 | PIM1 (0.40) | PIM1PIM2 | |
| SCHEMBL1438793 | 0.72 | PIM1 (0.35) | NTRK1FYNPIM1PIM2 | |
| SCHEMBL17464332 | 0.71 | PIM1 (0.39) | FYNPIM1PIM2 | |
| SCHEMBL23148335 | 0.69 | NTRK1 (0.43) | NTRK1NTRK3 | |
| SCHEMBL23148336 | 0.69 | NTRK1 (0.43) | NTRK1NTRK3 | |
| SCHEMBL20967402 | 0.68 | TGFBR2 (0.49) | NTRK1FYNPIM1PIM2TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | NTRK1 3204/4885FYN 2270/4885FGFR4 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.